Willingness to be Reinitiated on a Statin (from the REasons for Geographic and Racial Differences in Stroke Study)
| Autor: | Michael E. Farkouh, Monika M. Safford, Keri L. Monda, Gabriel S. Tajeu, Matthew T. Mefford, Rikki M. Tanner, Robert S. Rosenson, Paul Muntner, Lisandro D. Colantonio, Ricardo Dent |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
Male
medicine.medical_specialty Statin medicine.drug_class 030204 cardiovascular system & hematology Article Medication Adherence 03 medical and health sciences 0302 clinical medicine Internal medicine medicine Humans In patient cardiovascular diseases 030212 general & internal medicine Stroke Aged business.industry Middle Aged medicine.disease United States Confidence interval Discontinuation Cardiology Female lipids (amino acids peptides and proteins) Racial differences Statin therapy Hydroxymethylglutaryl-CoA Reductase Inhibitors Cardiology and Cardiovascular Medicine business After treatment |
| Zdroj: | Am J Cardiol |
| ISSN: | 0002-9149 |
| Popis: | Guidelines recommend attempting to re-initiate statins in patients who discontinue treatment. Prior experiences while taking a statin, including side effects, may reduce a person’s willingness to re-initiate treatment. We determined the percentage of adults who are willing to re-initiate statin therapy after treatment discontinuation. Factors associated with willingness to re-initiate a statin were also examined. A statin questionnaire was administered and study examination conducted among black and white US adults enrolled in the nationwide REasons for Geographic And Racial Differences in Stroke (REGARDS) study between 2013 and 2017. Among participants who self-reported ever having taken a statin (n=7,216, mean age 72 years, 53% women, 34% black), 1,081 (15%) reported having discontinued treatment. Among those who discontinued treatment, statin side effects, perceived lack of need for a statin, and cost were reported by 66%, 31%, and 3% of participants, respectively. Overall, 37% of participants who had discontinued treatment were willing to re-initiate statin therapy. Participants who discontinued treatment due to cost (prevalence ratio (PR) 1.61; 95% confidence interval (CI) 1.01, 2.57) were more likely to report a willingness to re-initiate therapy. Participants with a low-density lipoprotein-cholesterol ≥130 mg/dL versus |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect